You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

363 Results
Regimen
Regimen
Intent: Palliative
May 2020
Regimen
Intent: Palliative
Aug 2019
Regimen
Intent: Palliative
Nov 2019
Regimen
Intent: Palliative
Aug 2020
Regimen
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
  • melphalan - oral tablets
ODB - General Benefit
  • prednisone
Exceptional Access Program
  • thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
  • methotrexate - oral tablets
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Intent: Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
Funding:
ODB - General Benefit
  • procarbazine
ODB - General Benefit
  • prednisone
Jun 2019

Pages